Development of severe thrombocytopenia with TAFRO syndrome-like features in a patient with rheumatoid arthritis treated with a Janus kinase inhibitor
Authors:
- Keiichiro KadobaKKKeiichiro Kadoba
- Daisuke WakiDWDaisuke Waki
- Keisuke NishimuraKNKeisuke Nishimura
- Hiroki MukoyamaHMHiroki Mukoyama
- Rintaro SaitoRSRintaro Saito
- Hiroyuki MurabeHMHiroyuki Murabe
- Toshihiko YokotaTYToshihiko Yokota
Open Access
- 16 October 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 99 (42) , e22793
Abstract
Rationale: Thrombocytepenia, anasarca, fever, renal insufficiency, and organomegaly (TAFRO) syndrome is a novel disease entity characterized by a constellation of symptoms (thrombocytopenia, anasarca, fever, renal insufficiency, and organomegaly). Here, we describe the development of TAFRO syndrome-like features during the treatment of rheumatoid arthritis with a Janus kinase (JAK) inhibitor. Patient concerns: In this report, a 74-year-old woman treated with a JAK inhibitor (tofacitinib) for rheumatoid arthritis was admitted because of fever and thrombocytopenia. Diagnoses: On laboratory examination, marked thrombocytopenia and elevated creatinine and C-reactive protein levels were present. A computed tomography scan revealed lymphadenopathy, hepato-splenomegaly, and anasarca. A left axillary lymph node biopsy revealed Castleman's disease-like features. These clinical features satisfied the proposed diagnostic criteria for TAFRO syndrome. Since autoimmune disorders should be excluded when diagnosing TAFRO syndrome, it is not strictly correct to diagnose her as TAFRO syndrome. Therefore, we diagnosed her as rheumatoid arthritis complicated by TAFRO syndrome-like features. Interventions: The patient was treated with high-dose glucocorticoid, tacrolimus, eltrombopag, intravenous immunoglobulin, and rituximab. Outcomes: Her condition was refractory to the above-mentioned treatment, and she eventually died because of multi-organ failure 6 months after the first admission. Lessons: TAFRO syndrome-like features can develop during treatment with a JAK inhibitor for rheumatoid arthritis. Patients with autoimmune diseases complicated by TAFRO syndrome-like features can follow a fatal clinical course, and thus, an intensive combined treatment is warranted for such patients, especially in cases refractory to glucocorticoid.Keywords
This publication has 20 references indexed in Scilit:
- [Systemic lupus erythematosus with marked eosinophilia and clinical features mimicking TAFRO syndrome].2018
- Sjögren's syndrome manifesting as clinicopathological features of TAFRO syndromeMedicine, 2017
- JAK inhibition as a therapeutic strategy for immune and inflammatory diseasesNature Reviews Drug Discovery, 2017
- Rheumatoid arthritisThe Lancet, 2016
- Aggressive TAFRO syndrome with reversible cardiomyopathy successfully treated with combination chemotherapyInternational Journal of Hematology, 2016
- Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 versionInternational Journal of Hematology, 2016
- TAFRO syndrome with primary Sjogren's syndromeJapanese Journal of Clinical Immunology, 2016
- Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid ArthritisArthritis & Rheumatology, 2014
- Atypical Hyaline Vascular-Type Castleman's Disease With Thrombocytopenia, Anasarca, Fever, and Systemic LymphadenopathyJournal of Clinical and Experimental Hematopathology, 2013
- Multicentric Castleman’s disease representing effusion at initial clinical presentation: clinicopathological study of seven casesLupus, 2010